Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cannabinoid Hyperemesis Syndrome Clear all
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

NCT07726069
View directory record Official record
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
Haloperidol
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 7, 2026, 4:29 AM EST
Not listed Phase 3 Interventional Accepts healthy volunteers

Droperidol on Prevention of Cannabis Hyperemesis Syndrome

NCT05244460
View directory record Official record
Conditions
Cannabis Hyperemesis Syndrome
Interventions
Droperidol Injectable Product, Diphenhydramine
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Austintown, Ohio • Boardman, Ohio • Warren, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Nov 7, 2026, 4:29 AM EST
Completed Phase 3 Interventional

Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

NCT07246187
View directory record Official record
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
Olanzapine 10 milligram, Haloperidol
Drug
Lead sponsor
Mercy Bon Secours Saint Vincent Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 7, 2026, 4:29 AM EST
Completed Phase 4 Interventional

Capsaicin for the Treatment of Cannabinoid Hyperemesis Syndrome

NCT04283292
View directory record Official record
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
Capsaicin, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Nov 7, 2026, 4:29 AM EST